Articles

Filtered · 72

• Sharper Trial Enrichment for Cardiovascular Outcomes

  Using an Aurora prognostic signature to concentrate CV-death events and shrink outcomes trials.

  

  Tom Stubbs, PhD · CEO, Hurdle

  Published 28 July 2026

  Biomarker Science

  

• From Prognostic Signal to Drug Target

  Aurora’s discovered CV-death proteins map to established and emerging druggable biology.

  

  Tom Stubbs, PhD · CEO, Hurdle

  Published 9 July 2026

  Biomarker Science

  

• Multi-Protein Signatures Beat Single Biomarkers

  Why a proteomic panel predicts cardiovascular death in heart failure far better than NT-proBNP alone.

  

  Tom Stubbs, PhD · CEO, Hurdle

  Published 2 July 2026

  Biomarker Science

  

• What the ASCO 2026 Poster Hall Told Us About the Future of Diagnostics

  Five signals from this year's posters, and what they mean for anyone trying to take a biomarker from discovery to the clinic.

  

  Tom Stubbs, PhD · CEO, Hurdle

  Published 4 June 2026

  Industry News

  

• Algorithmic Risk Stratification for Clinical Trial Enrichment

  Moving beyond binary inclusion and exclusion criteria with ML-driven continuous risk scoring at population scale.

  

  Tom Stubbs, PhD · CEO, Hurdle

  Published 20 March 2026

  Biomarker Science

  

• At SCOPE 2026, One Message Was Clear: Clinical Innovation Has Entered Its Infrastructure Era

  

  Tom Stubbs, PhD · CEO, Hurdle

  Published 13 February 2026

  Biomarker Science

  

• Bringing Multi-Modal Intelligence to Early Clinical Recruitment

  

  Tom Stubbs, PhD · CEO, Hurdle

  Published 2 December 2025

  Biomarker Science

  

• Operational Precision for Modern Trials: Infrastructure That Keeps Sampling Aligned as Complexity Grows

  

  Tom Stubbs, PhD · CEO, Hurdle

  Published 2 December 2025

  Biomarker Science

  

• Taking our Multi-modal discovery engine to the Next Level – Meta-Analysis Part 1: Imputation

  

  Lisa Schmunk · Research & Development Manager, Hurdle

  Published 5 November 2025

  Biomarker Science

  

• Testing and Validating Your Diagnostics Pathway

  

  Rob Thompson · CTO & Co-founder, Hurdle

  Published 29 September 2025

  Diagnostics Infrastructure

  

• The Impact of Artificial Intelligence on Biomarker Discovery

  

  Jack Monahan · Senior Scientist, Hurdle

  Published 29 September 2025

  Biomarker Science

  

• End-to-end Omics Test Made Simple: Define and Manage Omics Tests at software speed with Hurdle

  

  Pierric Descamps · Senior Product Manager, Hurdle

  Published 28 August 2025

  Biomarker Science